MindMed's primary focus is on MM120, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the treatment of GAD. This designation is a significant milestone, as it indicates the FDA's recognition of MM120's potential to address an unmet medical need and may expedite the drug's development and review process.